GPs discriminated against on medical education pay
From Dr Dinesh Kapoor
CHD Lead, Waltham Forest PCT
The ASCOT trial (News, 10 September) is welcome news for the silently suffering hypertensive patients on ß-blockers who have been too embarrassed to complain about their erectile dysfunction side-effects.
For months now I have been practising and preaching the use of an ACE inhibitor or a calcium channel blocker in place of ß-blockers in hypertension and I am therefore for the ASCOT findings.
Let the Department of Health pick up the cost issue as saving cost would not be a good advert for the Government in this case.
Benefits of an ACE inhibitor are well-established in diabetes and CHD and let this class of drugs (or a sartan in case of intolerance) be the mainstream treatment for hypertension.